146 related articles for article (PubMed ID: 32769866)
21. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
Kim C; Mulder K; Spratlin J
Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
[TBL] [Abstract][Full Text] [Related]
22. E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer.
Li H; Zhao S; Shen L; Wang P; Liu S; Ma Y; Liang Z; Wang G; Lv J; Qiu W
Aging (Albany NY); 2021 Apr; 13(10):13626-13643. PubMed ID: 34091441
[TBL] [Abstract][Full Text] [Related]
23. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer.
Xu DZ; Geng QR; Tian Y; Cai MY; Fang XJ; Zhan YQ; Zhou ZW; Li W; Chen YB; Sun XW; Guan YX; Li YF; Lin TY
BMC Cancer; 2010 Oct; 10():536. PubMed ID: 20929525
[TBL] [Abstract][Full Text] [Related]
24. The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis.
Qiu W; Ren M; Wang C; Fu Y; Liu Y
Medicine (Baltimore); 2022 Dec; 101(51):e32340. PubMed ID: 36595789
[TBL] [Abstract][Full Text] [Related]
25. mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis.
Marques AE; Elias ST; Porporatti AL; Castilho RM; Squarize CH; De Luca Canto G; Guerra EN
J Oral Pathol Med; 2016 May; 45(5):319-28. PubMed ID: 26661562
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2).
Li N; Han M; Zhou N; Tang Y; Tang XS
Med Sci Monit; 2018 Aug; 24():5960-5972. PubMed ID: 30147110
[TBL] [Abstract][Full Text] [Related]
28. VEGFR-2 as a novel predictor of survival in gastric cancer: A systematic review and meta-analysis
.
Li T; Yu J; Luo X; Ren W; Zhang Y; Cao B
Pathol Res Pract; 2018 Apr; 214(4):560-564. PubMed ID: 29572120
[TBL] [Abstract][Full Text] [Related]
29. LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3β signaling.
Qiu YS; Jiang NN; Zhou Y; Yu KY; Gong HY; Liao GJ
Int J Mol Med; 2018 May; 41(5):2755-2763. PubMed ID: 29436606
[TBL] [Abstract][Full Text] [Related]
30. Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway.
Gao F; Li R; Wei PF; Ou L; Li M; Bai Y; Luo WJ; Fan Z
Bioengineered; 2022 Mar; 13(3):6332-6342. PubMed ID: 35209807
[TBL] [Abstract][Full Text] [Related]
31. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Gu L; Chen M; Guo D; Zhu H; Zhang W; Pan J; Zhong X; Li X; Qian H; Wang X
PLoS One; 2017; 12(8):e0182692. PubMed ID: 28796808
[TBL] [Abstract][Full Text] [Related]
33. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients.
Zhang C; Zhang CD; Ma MH; Dai DQ
World J Gastroenterol; 2018 Mar; 24(11):1206-1215. PubMed ID: 29568201
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive evaluation of single nucleotide polymorphisms associated with gastric cancer risk: A protocol for systematic review and network meta-analysis.
Ye ZM; Hu QY; Zheng JH; Zhang C; Zhu XD; Tang YM
Medicine (Baltimore); 2020 Jun; 99(25):e20448. PubMed ID: 32569167
[TBL] [Abstract][Full Text] [Related]
35. Relationships between abnormal MMP2 expression and prognosis in gastric cancer: a meta-analysis of cohort studies.
Wang HL; Zhou PY; Zhang Y; Liu P
Cancer Biother Radiopharm; 2014 May; 29(4):166-72. PubMed ID: 24784911
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.
Zhang Y; Li Z; Huang Y; Zou B; Xu Y
BMJ Open; 2024 Jan; 14(1):e073887. PubMed ID: 38296306
[TBL] [Abstract][Full Text] [Related]
37. [Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing Gastric Cancer Through Mammalian Target of Rapamycin].
Rao H; Cheng W; Yu J; An X; Deng H; Zhang Z; Wu F; Ji F; Li S
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1146-1153. PubMed ID: 38162062
[TBL] [Abstract][Full Text] [Related]
38. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
39. Prognostic implication of TSC1 and mTOR expression in gastric carcinoma.
Byeon SJ; Han N; Choi J; Kim MA; Kim WH
J Surg Oncol; 2014 Jun; 109(8):812-7. PubMed ID: 24615476
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.
Yu G; Wang J; Chen Y; Wang X; Pan J; Li G; Jia Z; Li Q; Yao JC; Xie K
Clin Cancer Res; 2009 Mar; 15(5):1821-9. PubMed ID: 19223493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
